Imatinib hy 15463

Manufactured by MedChemExpress

Imatinib (HY‐15463) is a small-molecule tyrosine kinase inhibitor. It is a white to off-white crystalline powder that is soluble in DMSO and ethanol.

Automatically generated - may contain errors

Lab products found in correlation

Gist t1, by Cosmo Bio (1 mentions) Cycloheximide c7698, by Merck Group (1 mentions) Mg132 m7449, by Merck Group (1 mentions)

Close spelling variants of this product

Imatinib

2 protocols using imatinib hy 15463

GIST Cell Lines Maintenance and Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human cell lines GIST‐882 and GIST‐430 were kindly gifted by Prof. Jonathan Fletcher (Brigham and Women's Hospital, Harvard Medical School), and GIST‐T1 was purchased from Cosmo Bio Co., Ltd. GIST‐T1 and 882 cells were maintained in RPMI1640 medium containing 10% fetal bovine serum (FBS) and 1% antibiotic mixture, while GIST‐430 cells were cultured in IMDM complete medium. All cells were incubated at 37℃ with 5% CO₂, and all experiments of cells were conducted in biohazard safety equipment.
Recombinant DKK4 protein (1269‐DK) was purchased from R&D Systems, and administrated with 500 ng/mL for inhibiting immune cells migration and activation. Imatinib (HY‐15463) was provided by MedChemExpress.

Wang M., Ni B., Zhuang C., Zhao W., Tu L., Ma X., Yang L., Zhang Z, & Cao H. (2019). Aberrant accumulation of Dickkopf 4 promotes tumor progression via forming the immune suppressive microenvironment in gastrointestinal stromal tumor. Cancer Medicine, 8(11), 5352-5366.

+ Open protocol

+ Expand

Antibody and Kinase Inhibitor Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used, from Cell Signaling Technology: anti-MYC (5605), anti-Pol II (14958), anti-pSTAT1Ser⁷²⁷ (8826), anti-STAT1 (14995), anti-pERK (4370), anti-ERK (9201), anti-CDK9 (2316); from AbCam: anti-pMYC Ser⁶² (ab106952), anti-pPol II Ser² (ab5095); from Sigma-Aldrich: anti-KRAS (WH0003845M1), anti-vinculin (V9131) from Santa Cruz Biotechnology: anti-MCL1 (sc-12756). The protein kinase inhibitors NVP-2 (HY-12214A), amuvatinib (HY-10206) and imatinib (HY-15463) were obtained from MedChemExpress, TC-S 7004 (5088) from Tocris Bioscience, and AZ 191 (5232) from Sigma-Aldrich. MG132 (M7449) and cycloheximide (C7698) were also obtained from Sigma-Aldrich. THAL-SNS-032 was a gift from Dr. Nathanael Gray (Harvard/DFCI). Synthetic schemes for UNC10112731 and UNC10112785 and derivatives are shown in Supplemental Methods.

Blake D.R., Vaseva A.V., Hodge R.G., Kline M.P., Gilbert T.S., Tyagi V., Huang D., Whiten G.C., Larson J.E., Wang X., Pearce K.H., Herring L.E., Graves L.M., Frye S.V., Emanuele M.J., Cox A.D, & Der C.J. (2019). Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Science signaling, 12(590), eaav7259.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!